9
Issues for
Committee Discussion
Adequacy
of evidence of safety and efficacy
–Any
gaps in data or other needed information?
Safety
areas of interest
–Risk
of malignancies
–Others
Impact
of raltegravir on design of future antiretroviral Phase 3
clinical trials for treatment-experienced subjects